AndhraNews.net
Home » Features » Health » Rhinitis

Rhinitis


About Rhinitis

Rhinitis, commonly known as a runny nose, is the medical term describing irritation and inflammation of some internal areas of the nose.

Oxymetazoline Hydrochloride Nasal Drops is a medicine for acute and chronic rhinitis, sinusitis and allergic rhinitis.

Allergic rhinitis (hay fever)

Allergic rhinitis (hay fever) is a reaction to indoor or outdoor airborne allergens, such as pollen. Longer pollen seasons and high levels of pollen certainly can exacerbate symptoms for people with allergic rhinitis and for those who previously had minimal symptoms.

A study in December 09 says that Allergic rhinitis quadruples the likelihood of asthma patients having poor control over their symptoms, thereby increasing the chance of an asthma attack.

Dr. Malkanthi Evans Scientific Director KGK Synergize Inc. says allergic rhinitis is often mistakenly believed to be a trivial health problem, while people suffering from hay fever may disagree as they experience a dramatic impairment to their quality of life.

Rhinitis in News

NeoBiocon Partners with Novartis to Offer Vildagliptin for Diabetics in UAE
Business Wire IndiaNeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE

Innovus Pharma Signs Exclusive License and Distribution Agreement With Bio Task for Malaysia
Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCQB: INNV) announced today it has entered into an exclusive license and distribution agreement with Bio Task SND BHD, a Malaysia company ("Bio Task")

Innovus Pharma Announces Formal of a Clinical Advisory Board to Support the Launch of Its Androferti(R) Product in the United States
Innovus Pharmaceuticals, Inc

Innovus Pharma Announces Publication of Fifth Successful Clinical Trial Involving Androferti(R)
Innovus Pharmaceuticals, Inc

Hans Christinger Joins Innovus Pharma's Advisory Board
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the addition of Mr. Christinger to the Company's Advisory Board. Mr

Innovus Pharma Added to the OTCQB Venture Index
Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, has announced today the Company was added to OTCQB Venture Index (http://www.otcmarkets.com/index/.OTCQB/constituents).

Innovus Pharma Expands Its Men's and Women's Health Franchise With the Addition of Exclusive Rights to AndroVit(R) to Support Overall Male Prostate and Sexual Health and Urocis(R) XR for Urinary Tract Infection (UTI) for Women From Q Pharma Spain
Innovus Pharmaceuticals, Inc

Innovus Pharmaceuticals Announces Sensum+(R) to Directly Increase Sensitivity in Pre-Clinical Studies Supporting Its Mechanism of Action and the Human Use Experience
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma

Regulatory Update: GSK and Theravance Announce Intention to File Relvar(R) Ellipta(R) for COPD in Japan
GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the intention to file a supplemental Japanese New Drug Application (sJNDA) for Relvar® Ellipta® (fluticasone furoate "FF"/vilanterol "VI" or "FF/VI") for the treatment of chronic obstructive pulmonary disease (COPD) with the Japanese regulatory authority during the first quarter of 2016

GSK and Theravance Announce Results From the SUMMIT COPD CV Survival Study
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for Relvar®/Breo® Ellipta® 100/25mcg (fluticasone furoate 'FF'/vilanterol 'VI' or 'FF/VI')

FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia
Novartis International AG /FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombocytopenia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder
Novartis International AG /Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Allergy Ad Packs a Punch
New ads and sales materials, created by Glue Advertising for Meda Pharmaceuticals' seasonal nasal allergy medication Dymista® (azelastine hydrochloride and fluticasone propionate) nasal spray, demonstrate how provocative, insight-based images can capture the attention of consumers and physicians and convey important healthcare information.

FDA Approves BREO(R) ELLIPTA(R) for the Treatment of Adults With Asthma in the US
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) for the once-daily treatment of asthma in patients aged 18 years and older. Breo Ellipta is not indicated for the relief of acute bronchospasm.

Dr. Mariana Marcu, Top 3 Ways to Battle Allergies This Winter in NYC
Dr. Mariana Marcu addresses everyone's concerns this flu season, as she states, "Winter is the best time to treat your allergies!"

Vernalis Opens US Office and Strengthens US Team With the Appointment of SVP Medical Affairs
Vernalis plc (LSE: VER) today announces it has opened its US office in Berwyn, Pennsylvania and has strengthened its US Executive team with the appointment of Dr Pascal Borderies, as SVP Medical Affairs. A physician by training, Pascal joins Vernalis from Actavis' subsidiary company Aptalis Pharma, Inc

New eHealth Choice & Impact Study: Average Medicare Beneficiary Could Have Saved $961 on Prescription Drugs in 2014
eHealth, Inc. (NASDAQ: EHTH) today published an analysis of over 22,000 people who used the online Medicare plan comparison tools at eHealthMedicare.com and PlanPrescriber.com during Medicare's 2014 Annual Enrollment Period (AEP -- also referred to as the Election Period)

Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.

Adamis Pharmaceuticals Announces Private Placement
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare institutional fund and received gross cash proceeds of approximately $5,000,000

FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS), for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

Adamis Pharmaceuticals Announces Investor Update Live Webcast
Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) ("the Company") will host a live webcast on Monday, June 16, 2014 at 4:15pm ET to provide a business update concerning the Company's recent corporate developments. The Company's President and CEO, Dr. Dennis Carlo, will host the call.

Adamis Pharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it will present at the 9th Annual JMP Securities Healthcare Conference at The Westin New York Grand Central on Wednesday, June 25, 2014. President and CEO, Dr. Dennis Carlo, is scheduled to present at 12:30 p.m. Eastern Time.

Allergy Partners Hang New Shingle: Veteran Allergist Dr. Bruce Prenner, Dr. Jennifer Pendleton & Staff Relocate to Mission Valley
After more than 30 years of being based in the Alvarado Medical vicinity, doctors Bruce Prenner and Jennifer Pendleton have relocated to Mission Valley, where patients will be able to visit their state-of-the-art medical facility in the heart of San Diego.

Adamis CEO Dr. Dennis J. Carlo to Present at the LD Micro Invitational Conference Today
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced it will present at the LD Micro Invitational Conference today at the Luxe Sunset Boulevard Hotel in Los Angeles.

Adamis Submits New Drug Application to FDA for Its Epinephrine Pre-Filled Syringe
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its epinephrine pre-filled single dose syringe (PFS) product. Specifically the EPINEPHRINE INJECTION, USP, 1:1000 (0

Cold or Allergies: A Guide to Knowing the Difference
As Spring is beginning to bud around us, the pollen forecast is looking heavy. With the significantly snowy winter that we all experienced, we can expect full-on pollen production. When you start to feel that tickle in your nose, you need to be able to decide "is it really allergies, or have I caught a cold?"

Allergic Asthma: Could Allergies Be Triggering Your Asthma?
In the U.S., there are an estimated 25 million asthma sufferers. For many of those sufferers, treatment involves a combination of medication for long-term symptoms and quick relief during an asthma attack. While managing symptoms and stopping an attack are top asthma priorities, next on the list of importance is identifying triggers

Adamis Receives Notice of Key Allowance for US Patent That Supports Its Cancer Immunology Portfolio
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced an important addition to its intellectual property with receipt of a Notice of Allowance of patent claims supporting its cancer immunotherapy portfolio in the United States. Notice of Allowance is the final step in the issuance of a patent

Adamis Pharmaceuticals Announces Full Exercise of Underwriter's Over-Allotment Option
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 558,000 shares of common stock at a public offering price of $5

Adamis Pharmaceuticals Announces Completion of Acquisition

Medical Cannabis Financial Group, Inc. Announces Merger Transaction With Refill Energy, Inc.
Refill Energy, Inc. (PINKSHEETS: REFG), a Nevada Corporation (the "Company") announces the merger between Refill Energy, Inc. and Medical Cannabis Financial Group. Refill Energy, Inc. completed a reorganization with Medical Cannabis Financial Group, Inc., which is a software solutions company focused on solutions for the Medical Marijuana industry

Pharming and Santarus announce poster presentation of pivotal clinical data for RUCONEST(R) (recombinant human C1 esterase inhibitor)
Pharming Group NV(NYSE Euronext: PHARM) and Santarus, Inc

Celsus Therapeutics Strengthens Board of Directors With Addition of Dermatology Industry Veteran Robert F. Doman
Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced the addition of industry veteran Robert F. Doman to the Company's Board of Directors.

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share. The gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.

Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are expected to be approximately $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses

Adamis Pharmaceuticals Announces Proposed Public Offering
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants. The filing covers up to $25 million in securities

RELVAR(R) ELLIPTA(R) Receives European Marketing Authorisation for the Treatment of Asthma and COPD
GlaxoSmithKline plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced today that the European Commission has granted marketing authorisation for RELVAR® ELLIPTA®, which is now licensed across 31 European countries for the following uses:

Plandai Biotechnology, Inc. Executes Letter of Intent to Sell All Estimated 2014 Phytofare Limonoid Production
Plandaí Biotechnology, Inc

RELVAR(TM) ELLIPTA(TM) Receives Positive Opinion From the CHMP in Europe for the Treatment of Asthma and COPD
GlaxoSmithKline plc (NYSE: GSK) (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/vilanterol (FF/VI) under the proposed brand name RELVAR™ ELLIPTA™ for;

Adamis Announces Positive Results of Study Concerning C31G in Treating Herpes Simplex Virus (HSV) Eye Infection
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that a recently published study conducted by university researchers found that the company's antimicrobial and spermicidal agent, C31G, was effective in treating Herpes Simplex Virus (HSV) in an eye infection (ocular keratitis) animal model

Adamis Prostate Cancer Drug Receives Allowance for Patent in USA

Adamis Pharmaceuticals Announces Investor Update Conference Call
Adamis Pharmaceuticals Corp

CHILDREN'S CLARITIN(R) and KaBOOM! Help Bring Play to Kids and Communities in Need
Merck Consumer Care, the makers of CHILDREN'S CLARITIN®, today announced a new program with national nonprofit KaBOOM!, to help bring innovative play spaces to schools in need. The campaign is engaging parents on the Claritin Facebook page, asking them to vote for one of 12 finalist schools

Adamis Pharmaceuticals Announces Private Placement
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) announced today that it has completed a private placement financing transaction pursuant to which it issued senior secured convertible promissory notes and warrants to purchase up to 13,004,316 shares of common stock, to a small number of institutional investors and received gross cash proceeds of $5,300,000

Celsus Therapeutics Announces Positive Phase II Interim Results for MRX-6 in the Treatment of Contact Dermatitis
Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotechnology company, announced today positive interim results from the first cohort (2% MRX-6 vs. vehicle) of a multi-center Phase II double blind, two step dose-ranging, vehicle and active control study of MRX-6 for the treatment of patients with allergic contact dermatitis (ACD)

Celsus Therapeutics Announces Notification of Patents Granted

Ares Life Sciences to Acquire Antigen Laboratories, Inc., in the United States
Ares Life Sciences, a healthcare-focused investment group, announced today that it has signed a definitive agreement to acquire 100% of the share capital of Planet Biopharmaceuticals, Inc., including its wholly owned subsidiary Antigen Laboratories, Inc., a producer of allergen extracts, who works closely with the ENT (Ear, Nose and Throat) specialist community in the United States

LifeSci Advisors Initiates Coverage of Celsus Therapeutics
LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Celsus Therapeutics PLC

Ares Life Sciences to Acquire GREER(R) Laboratories, Inc., a Leader in Allergy Immunotherapy in the United States
Ares Life Sciences, a healthcare-focused investment group, announced today that it has signed a definitive agreement to acquire 100% of the share capital of Albion Medical Holdings, Inc., including its wholly owned subsidiary GREER® Laboratories, Inc., a leader in allergy immunotherapy in the United States. Closing of the transaction is subject to U.S

DISREGARD PREVIOUS RELEASE - RECORDATI: Board approves the 2012 accounts.
RECORDATI: BOARD APPROVES THE 2012 ACCOUNTS. REVENUE EUR 828.3 MILLION(+8.7%),OPERATING INCOME EUR 167.0 MILLION (+2.1%), NET INCOME EUR 118.5 MILLION(+1.8%).2012 DIVIDEND EUR 0.30. * Consolidated revenue EUR 828.3 million, + 8.7%. * Operating income EUR 167.0 million, + 2.1%. * Net income EUR 118.5 million, + 1.8%

Santarus and Pharming announce positive Top-Line Phase III results for RUCONEST in acute Hereditary Angioedema
Statisticallysignificant results for primary endpoint of time to beginning of symptomrelief

Recordati : Positive First Nine Months 2012 Results
* Consolidated revenue EUR 620.3 million, + 6.8%. * Operating income EUR 132.4 million, + 2.7%. * Net income EUR 93.1 million, + 1.2%. * Net financial position*: net debt of EUR 44.6 million. * Start of phase III clinical trials concerning REC 0482 (NX-1207), an innovative BPH treatment

Recordati: Positive First Half 2012 Results (Revenue +4.7%, Net Income +1.5%)
POSITIVE FIRST HALF 2012 RESULTS (REVENUE +4.7%, NET INCOME +1.5%) THANKS TOTHEGROWTH OF THE INTERNATIONAL BUSINESS (+9.1%) * Consolidated revenue EUR 419.9 million, + 4.7%. * Operating income EUR 90.2 million, + 2.3%. * Net income EUR 63.3 million, + 1.5%. * Net financial position*: net debt of EUR 66.6 million

Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board
Morria Biopharmaceuticals Plc., a biopharmaceutical company focused on developing novel, first-in-class, synthetic, non-steroidal anti-inflammatory drugs, announced today that it has appointed Charles Serhan Ph.D. to its Scientific Advisory Board (SAB)

Pharming announces presentation of new Ruconest(R) clinical data

Recordati: Good First Quarter 2012 Results (Revenue +11.0%, Net Income +7.5%)
-- Consolidated revenue EUR 219.6 million, + 11.0%.-- Operating income EUR 47.6 million, + 7.5%.-- Net income EUR 33.8 million, + 7.5%.-- Net financial position*: net debt of EUR 54.1 million.-- Start of phase III clinical trials concerning REC 0482 (NX-1207), aninnovative BPH treatment

ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of BEPOSONE(TM) Nasal Spray for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) announced today positive results from its Phase 2 randomized, placebo-controlled, parallel-group environmental clinical study of BEPOSONE™ (bepotastine besilate/steroid) nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies

RECORDATI Acquires Six OTC Products in Germany
Recordati announces the acquisition of themarketingauthorizations, the trademarks and additional assets concerning sixOTCpharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH& Co.oHG

Actelion announces first quarter 2012 financial results
Actelion Pharmaceuticals Ltd /Actelion announces first quarter 2012 financial results. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Actelion provides update on CRTH2 program
Actelion Pharmaceuticals Ltd /Actelion provides update on CRTH2 program. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Emergency Animal Hospital Warns Pet Owners About the Dangers of Pet Allergies
Emergency Animal Hospital of Northwest Austin is warning pet owners about the dangers of allergies in pets. According to the practice, the emergency vet clinic frequently treats pets for allergy symptoms. Cat and dog symptoms may vary depending on the type of allergen and the animal's allergen tolerance

ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) announced today financial results for the quarter and the year ended December 31, 2011.

Actelion announces Full Year 2011 financial results
Actelion Pharmaceuticals Ltd /Actelion announces Full Year 2011 financial results. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ISTA Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), today announced it has successfully enrolled more than 600 patients in the Company's Phase 2 clinical study of its BEPOSONE™ nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies

Ora Executives to Present at Allergy Drug Discovery & Development Conference in San Diego
Leading allergy experts from Ora, Inc. will present at the GTC Bio Allergy Drug Discovery & Development Conference in San Diego. The meeting, taking place January 30-31st at the Paradise Point Resort & Spa in San Diego, CA, will offer insight from Mark Abelson, MD, CM, FRCSC, FARVO, Scientific Advisor, Founder, Ora, Inc.; Paul Gomes, MS, Vice President, Allergy, Ora, Inc

Actelion to present at the 30th Annual J.P. Morgan Healthcare Conference - Getting ready for Actelion's next growth phase
Actelion Pharmaceuticals Ltd /Actelion to present at the 30th Annual J.P. Morgan Healthcare Conference - Getting ready for Actelion's next growth phase . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ISTA Pharmaceuticals Announces Preliminary 2011 Revenue Results; Provides 2012 Financial Guidance and Updates Key Pipeline Milestones
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced during its 2012 Guidance and Pipeline Update webcast/conference call that it expects to achieve 2011 net revenues above $160 million and expects to be profitable in 2011 for the second consecutive year on an adjusted cash net income basis, according to preliminary unaudited estimates.

ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of BEPOSONE(TM) (Bepotastine Besilate - Steroid Combination Nasal Spray) for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced it has initiated a Phase 2 clinical study of its BEPOSONE™ nasal spray combining bepotastine besilate with a steroid for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies

C- section delivery may double childhood obesity risk
Babies, who are born by caesarean section, may be twice more likely to face the risk of obesity as compared to infants delivered vaginally, according to a new study.

Nasal spray containing hot chili peppers may help ease sinus problems
A new study has found that hot chili peppers, which usually make people "tear up", may help people "clear up" certain types of sinus inflammation.

Now, pine tree powder can cure hay fever
Researchers have found a possible cure of hay fever that is plagued by itchy eyes and a runny nose in summer. The sufferers may find relief in a powder produced from pine trees.

Actelion announces Half Year 2011 financial results
Actelion Pharmaceuticals Ltd /Actelion announces Half Year 2011 financial results. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis
Novartis International AG /Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

FDA accepts filing of New Drug Application for Nycomed's ciclesonide HFA nasal aerosol
Nycomed /FDA accepts filing of New Drug Application for Nycomed's ciclesonide HFA nasal aerosol . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Ninety Five 5 and PLAYER MAP Offer Integrated Strategic and Tactical Sales Expertise
Ninety Five 5, an execution-focused sales transformation platform, and PLAYER MAP, a strategic visual sales process, today announced that the complementary sales philosophies have been tightly integrated into Ninety Five 5's Sales Success System (S3), an innovative sales performance methodology

ISTA Pharmaceuticals Reports First Quarter 2011 Financial Results
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA), todayreported financial results and progress on key milestones for the quarterended March 31, 2011.

ISTA Pharmaceuticals Reports Positive, Topline Results From Its Phase 2 Clinical Trial of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated With Seasonal Allergic Rhinitis
ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced positive, topline results from its Phase 2 dose-ranging, environmental clinical trial of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies

MEDA/Online survey on treating allergic rhinitis: Patients mostly want to improve their quality of life
CGC /MEDA/Online survey on treating allergic rhinitis: Patients mostly want to improve their quality of life . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

First-born kids 'more likely to suffer from allergies'
First-born children are more likely to suffer from allergies than their younger brothers and sisters, Japanese scientists have found.

Comment on this story

Share